AstraZeneca and Pillar Biosciences Partner to Accelerate Access to Liquid Biopsy Testing
Pillar Biosciences and AstraZeneca seek to expand access to NGS-based liquid biopsy tumor profiling to detect genetic cancer variants.
Read MorePosted by Andy Lundin | Sep 18, 2024 | Molecular Diagnostics |
Pillar Biosciences and AstraZeneca seek to expand access to NGS-based liquid biopsy tumor profiling to detect genetic cancer variants.
Read MorePosted by Andy Lundin | Sep 18, 2024 | Diabetes & Metabolic Diseases |
A new study encourages the use of more reliable tests to prevent pregnancy complications and the development of type II diabetes.
Read MorePosted by Chris Wolski | Sep 16, 2024 | Specimen Collection & Handling |
Truvian CEO Jay Srinivasan outlines how the company’s instrument could revolutionize blood testing at the point-of-care.
Read MorePosted by Andy Lundin | Sep 16, 2024 | Emerging & Zoonotic Diseases |
ARUP Laboratories has been selected by the CDC to develop a rapid-response test for H5N1, addressing the ongoing public health crises.
Read MorePosted by Andy Lundin | Sep 16, 2024 | Emerging & Zoonotic Diseases |
Virax Biolabs extended its distribution agreement with Cosmos Health to commercialize its Mpox kits in the Gulf Cooperation Council.
Read More